Abstract
Tuberculosis (TB) remains to be a global major public-health threat, causing millions of deaths each year. A major difficulty in dealing with TB is that the causative bacterium, Mycobacterium tuberculosis, can persist in host tissue for a long period of time even after treatment. Mycobacterial persistence has become a central research focus for developing next-generation TB drugs. Latest genomic technology has enabled a high-throughput approach for identifying potential TB drug targets. Each gene product can be screened for its uniqueness to the TB metabolism, host-pathogen discrimination, essentiality for survival, and potential for chemical binding, among other properties. However, the exhaustive search for useful drug targets over the entire genome would not be productive as expected in practice. On the other hand, the problem can be formulated as pattern recognition or inductive learning and tackled with rule-based or statistically based learning algorithms. Here we review the perspective that combines machine learning and genomics for drug discovery in tuberculosis.
Keywords: Tuberculosis, persistence, machine learning, microarray, drug target.
Current Pharmaceutical Design
Title:Machine Learning and Tubercular Drug Target Recognition
Volume: 20 Issue: 27
Author(s): Li M. Fu
Affiliation:
Keywords: Tuberculosis, persistence, machine learning, microarray, drug target.
Abstract: Tuberculosis (TB) remains to be a global major public-health threat, causing millions of deaths each year. A major difficulty in dealing with TB is that the causative bacterium, Mycobacterium tuberculosis, can persist in host tissue for a long period of time even after treatment. Mycobacterial persistence has become a central research focus for developing next-generation TB drugs. Latest genomic technology has enabled a high-throughput approach for identifying potential TB drug targets. Each gene product can be screened for its uniqueness to the TB metabolism, host-pathogen discrimination, essentiality for survival, and potential for chemical binding, among other properties. However, the exhaustive search for useful drug targets over the entire genome would not be productive as expected in practice. On the other hand, the problem can be formulated as pattern recognition or inductive learning and tackled with rule-based or statistically based learning algorithms. Here we review the perspective that combines machine learning and genomics for drug discovery in tuberculosis.
Export Options
About this article
Cite this article as:
Fu M. Li, Machine Learning and Tubercular Drug Target Recognition, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118164023
DOI https://dx.doi.org/10.2174/1381612819666131118164023 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure-Based Drug Design to Overcome Drug Resistance: Challenges and Opportunities
Current Pharmaceutical Design Intracellular Life of Coxiella burnetii in Macrophages: Insight into Q Fever Immunopathology
Current Immunology Reviews (Discontinued) Tuberculosis: Current Treatment and New Drug Development
Anti-Infective Agents in Medicinal Chemistry Cutaneous Adverse Drug Reactions Caused by Antituberculosis Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio
Current Medicinal Chemistry Fighting Diabetes: Lessons from Xenotransplantation and Nanomedicine
Current Pharmaceutical Design Expression, Purification, Crystallization and Preliminary X-Ray Crystallographic Analysis of the Peptidoglycan Binding Region of the Ser/Thr Kinase PrkC from Staphylococcus aureus
Protein & Peptide Letters Editorial
Current Drug Targets - Infectious Disorders Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology A Computational Study of Molecular Interactions and In Vitro Antibacterial Activity of 6-Substituted Quinoline Carboxylic Acid Derivatives as DNA Gyrase Inhibitors
Letters in Drug Design & Discovery Morpholine Based Diazenyl Chalcones: Synthesis, Antimicrobial Screening and Cytotoxicity Study
Anti-Cancer Agents in Medicinal Chemistry Structure-based Drugs Design Studies on Spleen Tyrosine Kinase Inhibitors
Letters in Drug Design & Discovery Health Benefits of Ipecac and Cephaeline: their Potential in Health Promotion and Disease Prevention
Current Bioactive Compounds Editorial [ Infectious Disorders Drug Targets - An Arsenal of Knowledge on Pathogen Targets ]
Infectious Disorders - Drug Targets State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience Oral Mucosal Immunization: Recent Advancement and Future Prospects
Current Immunology Reviews (Discontinued) DFT Based QSAR/QSPR Models in the Development of Novel Anti-tuberculosis Drugs Targeting Mycobacterium tuberculosis
Current Pharmaceutical Design Advanced in Silico Methods for the Development of Anti- Leishmaniasis and Anti-Trypanosomiasis Agents
Current Medicinal Chemistry In Vivo Induced Antigen Technology (IVIAT) and Change Mediated Antigen Technology (CMAT)
Infectious Disorders - Drug Targets Antimycotic Drugs and their Mechanisms of Resistance to <i>Candida</i> Species
Current Drug Targets